GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Arctic Bioscience AS (OSL:ABS) » Definitions » ROIC %

Arctic Bioscience AS (OSL:ABS) ROIC % : -26.53% (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Arctic Bioscience AS ROIC %?

ROIC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROC %. Arctic Bioscience AS's annualized return on invested capital (ROIC %) for the quarter that ended in Dec. 2023 was -26.53%.

As of today (2024-05-05), Arctic Bioscience AS's WACC % is 1.03%. Arctic Bioscience AS's ROIC % is -26.27% (calculated using TTM income statement data). Arctic Bioscience AS earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Arctic Bioscience AS ROIC % Historical Data

The historical data trend for Arctic Bioscience AS's ROIC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Arctic Bioscience AS ROIC % Chart

Arctic Bioscience AS Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROIC %
Get a 7-Day Free Trial -6.93 -36.23 -47.00 -28.04 -26.87

Arctic Bioscience AS Semi-Annual Data
Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
ROIC % Get a 7-Day Free Trial Premium Member Only Premium Member Only -38.52 -26.55 -27.92 -25.36 -26.53

Competitive Comparison of Arctic Bioscience AS's ROIC %

For the Biotechnology subindustry, Arctic Bioscience AS's ROIC %, along with its competitors' market caps and ROIC % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Arctic Bioscience AS's ROIC % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Arctic Bioscience AS's ROIC % distribution charts can be found below:

* The bar in red indicates where Arctic Bioscience AS's ROIC % falls into.



Arctic Bioscience AS ROIC % Calculation

Arctic Bioscience AS's annualized Return on Invested Capital (ROIC %) for the fiscal year that ended in Dec. 2023 is calculated as:

ROIC % (A: Dec. 2023 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (A: Dec. 2022 ) + Invested Capital (A: Dec. 2023 ))/ count )
=-48.586 * ( 1 - 0% )/( (162.839 + 198.768)/ 2 )
=-48.586/180.8035
=-26.87 %

where

Invested Capital(A: Dec. 2022 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=327.702 - 21.702 - ( 143.161 - max(0, 40.422 - 198.327+143.161))
=162.839

Arctic Bioscience AS's annualized Return on Invested Capital (ROIC %) for the quarter that ended in Dec. 2023 is calculated as:

ROIC % (Q: Dec. 2023 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jun. 2023 ) + Invested Capital (Q: Dec. 2023 ))/ count )
=-52.002 * ( 1 - 0% )/( (193.33 + 198.768)/ 2 )
=-52.002/196.049
=-26.53 %

where

Note: The Operating Income data used here is two times the semi-annual (Dec. 2023) data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Arctic Bioscience AS  (OSL:ABS) ROIC % Explanation

ROIC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROIC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, Arctic Bioscience AS's WACC % is 1.03%. Arctic Bioscience AS's ROIC % is -26.27% (calculated using TTM income statement data).


Be Aware

Like ROE % and ROA %, ROIC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.


Arctic Bioscience AS ROIC % Related Terms

Thank you for viewing the detailed overview of Arctic Bioscience AS's ROIC % provided by GuruFocus.com. Please click on the following links to see related term pages.


Arctic Bioscience AS (OSL:ABS) Business Description

Traded in Other Exchanges
N/A
Address
Industrivegen 42, Orsta, NOR, 6155
Arctic Bioscience AS is a Norwegian biotechnology company. The company is focused on developing products and solutions based on bioactive marine compounds. The product portfolio includes nutraceuticals and pharmaceuticals. It is currently developing a novel, cost-efficient oral treatment (HRO350) for mild-to-moderate psoriasis. Its nutraceutical products are sold globally to both B2C and B2B under the Romega brand.

Arctic Bioscience AS (OSL:ABS) Headlines

No Headlines